David Raben Selected Research

David Raben Research Topics

Disease

77	Neoplasms (Cancer) 01/2022 - 02/2002
41	Squamous Cell Carcinoma of Head and Neck 01/2024 - 12/2004
30	Head and Neck Neoplasms (Head and Neck Cancer) 12/2019 - 08/2002
15	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 03/2003
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2002
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 04/2008
7	Lung Neoplasms (Lung Cancer) 08/2011 - 02/2002
6	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2006
6	Squamous Cell Neoplasms (Squamous Cell Cancer) 04/2017 - 12/2004
5	Mucositis 01/2019 - 04/2006
5	Carcinoma (Carcinomatosis) 01/2017 - 08/2006
3	Stomatitis 01/2022 - 04/2013
3	Breast Neoplasms (Breast Cancer) 11/2020 - 08/2002
3	Oropharyngeal Neoplasms 01/2019 - 09/2010
3	Laryngeal Neoplasms (Laryngeal Cancer) 02/2017 - 01/2017
3	Deglutition Disorders (Dysphagia) 01/2016 - 11/2010
3	Exanthema (Rash) 01/2016 - 11/2007
2	Mouth Neoplasms (Oral Cancer) 01/2022 - 01/2019
2	Melanoma (Melanoma, Malignant) 10/2018 - 04/2011
2	Inflammation (Inflammations) 01/2017 - 01/2012
2	Tonsillar Neoplasms 06/2015 - 08/2009
2	Hemorrhage 01/2012 - 11/2010
2	Disease Progression 11/2010 - 02/2006
2	Lymphatic Metastasis 11/2009 - 08/2006
2	Xerostomia 08/2009 - 04/2008
2	Adenocarcinoma 04/2009 - 06/2008
2	Pancreatic Neoplasms (Pancreatic Cancer) 04/2009 - 12/2006
2	Colonic Neoplasms (Colon Cancer) 11/2005 - 10/2002
1	Hyperlipidemias (Hyperlipidemia) 01/2019
1	Fibrosis (Cirrhosis) 01/2019
1	Dermatitis 10/2018
1	Brain Neoplasms (Brain Tumor) 10/2018

Drug/Important Bio-Agent (IBA)

16	ErbB Receptors (EGF Receptor)IBA 03/2016 - 02/2002
14	Cetuximab (Erbitux)FDA Link 11/2020 - 08/2002
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2005
11	Gefitinib (Iressa)FDA Link 07/2011 - 02/2002
9	Cisplatin (Platino)FDA LinkGeneric 09/2017 - 01/2005
9	Tyrosine Kinase InhibitorsIBA 04/2009 - 02/2002
7	Biomarkers (Surrogate Marker)IBA 01/2018 - 06/2007
6	vandetanib (ZD6474)IBA 03/2016 - 08/2005
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2009 - 08/2005
4	Prostate-Specific Antigen (Semenogelase)IBA 04/2016 - 04/2014
4	Docetaxel (Taxotere)FDA Link 09/2015 - 04/2007
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2006 - 07/2004
3	durvalumabIBA 01/2024 - 11/2022
3	AndrogensIBA 01/2022 - 03/2016
3	Therapeutic UsesIBA 01/2022 - 04/2013
3	olaparibIBA 11/2020 - 10/2018
3	Growth Factor ReceptorsIBA 04/2015 - 01/2006
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2012 - 08/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2010 - 12/2006
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2006 - 02/2002
3	Monoclonal AntibodiesIBA 02/2006 - 08/2004
2	Small Interfering RNA (siRNA)IBA 01/2018 - 08/2006
2	Messenger RNA (mRNA)IBA 01/2018 - 08/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 12/2006
2	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2017 - 04/2013
2	Phosphotransferases (Kinase)IBA 12/2016 - 08/2005
2	bouvardinIBA 10/2015 - 05/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 05/2012 - 04/2009
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 08/2011 - 10/2002
2	Cytotoxins (Cytolysins)IBA 07/2011 - 06/2009
2	Gemcitabine FDA Link 06/2009 - 12/2006
2	von Willebrand FactorIBA 09/2008 - 08/2004
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2006 - 08/2005
2	AntibodiesIBA 07/2004 - 08/2002
1	CytokinesIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	tat Gene Products (tat Protein)IBA 01/2022
1	B7-H1 AntigenIBA 01/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2021
1	Poly Adenosine Diphosphate RiboseIBA 11/2020
1	HomoharringtonineIBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2019
1	AntigensIBA 11/2019
1	ChemokinesIBA 11/2019
1	Oncogene Proteins (Oncogene Protein)IBA 11/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	LipidsIBA 01/2019
1	human SMAD7 proteinIBA 01/2019
1	atezolizumabIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018

Therapy/Procedure

76	Radiotherapy 01/2022 - 08/2002
46	Therapeutics 01/2022 - 01/2004
17	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
7	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 10/2018 - 04/2005
6	Immunotherapy 01/2019 - 07/2004
6	Chemoradiotherapy 12/2017 - 11/2007
3	Combined Modality Therapy 01/2018 - 09/2009
3	Induction Chemotherapy 02/2017 - 09/2011
3	Aftercare (After-Treatment) 01/2017 - 03/2003
2	Neoadjuvant Therapy 01/2019 - 08/2017
2	Brachytherapy 05/2016 - 03/2016
2	Enteral Nutrition (Feeding, Tube) 01/2016 - 12/2012
2	Prostatectomy (Retropubic Prostatectomy) 04/2014 - 02/2010
2	Re-Irradiation 01/2014 - 11/2010
2	Withholding Treatment 08/2005 - 10/2002
1	Radioimmunotherapy 01/2019
1	Metastasectomy 10/2018